Need professional-grade analysis? Visit stockanalysis.com
$463.41M
N/A
46
N/A
BioPorto (BIOPOR) trades on Nasdaq Copenhagen in DKK. The company is classified in the Healthcare sector under the Diagnostics & Research industry. The stock currently trades at DKK0.94, down 1.06% from the previous close.
Over the past year, BIOPOR has traded between a low of DKK0.84 and a high of DKK1.59. The stock has lost 36.3% over this period. It is currently 41.1% below its 52-week high.
BioPorto has a market capitalization of $463.41M.
BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the onset of disease states for management and therapies in Europe, North America, Asia, and internationally. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine, EDTA plasma, or heparin plasma on automated clinical chemistry analyzers to diagnose acute kidney injury; and antibodies to develop diagnostic immunoassays within disease areas, including immunodeficiency, allergy, coagulation, diabetes, kidney, and cardiovascular disease. The company also provides ready-to-use enzyme-linked immunosorbent assay (ELISA) kits to quantify NGAL in urine, plasma, and serum; and generic Rapid Assay Device (gRAD) for custom lateral flow assays. BioPorto A/S was founded in 1917 and is based in Hellerup, Denmark.
Side-by-side comparison against top Healthcare peers.